Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free SBOT Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Stellar Biotechnologies (SBOT) Competitors

Stellar Biotechnologies logo
Compare

SBOT vs. CNTN, MENS, ANTX, TTRX, and AADI

Should you be buying Stellar Biotechnologies stock or one of its competitors? The main competitors of Stellar Biotechnologies include Hillstream Biopharma (CNTN), Jyong Biotech (MENS), Anthem (ANTX), Turn Therapeutics (TTRX), and Aadi Bioscience (AADI).

How does Stellar Biotechnologies compare to Hillstream Biopharma?

Hillstream Biopharma (NASDAQ:CNTN) and Stellar Biotechnologies (NASDAQ:SBOT) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 1.7% of Stellar Biotechnologies shares are owned by institutional investors. 6.7% of Hillstream Biopharma shares are owned by insiders. Comparatively, 7.8% of Stellar Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Stellar Biotechnologies has higher revenue and earnings than Hillstream Biopharma. Stellar Biotechnologies is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hillstream BiopharmaN/AN/A-$35.92M-$3.99N/A
Stellar Biotechnologies$210K212.44-$5.03M-$1.76N/A

Hillstream Biopharma has a net margin of 0.00% compared to Stellar Biotechnologies' net margin of -1,782.64%. Hillstream Biopharma's return on equity of -35.59% beat Stellar Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Hillstream BiopharmaN/A -35.59% -27.05%
Stellar Biotechnologies -1,782.64%-51.12%-48.37%

In the previous week, Hillstream Biopharma's average media sentiment score of 0.00 equaled Stellar Biotechnologies'average media sentiment score.

Company Overall Sentiment
Hillstream Biopharma Neutral
Stellar Biotechnologies Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hillstream Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Stellar Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Hillstream Biopharma and Stellar Biotechnologies tied by winning 5 of the 10 factors compared between the two stocks.

How does Stellar Biotechnologies compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Stellar Biotechnologies (NASDAQ:SBOT) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

1.7% of Stellar Biotechnologies shares are owned by institutional investors. 7.8% of Stellar Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Jyong Biotech has higher earnings, but lower revenue than Stellar Biotechnologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jyong BiotechN/AN/AN/AN/AN/A
Stellar Biotechnologies$210K212.44-$5.03M-$1.76N/A

Jyong Biotech has a net margin of 0.00% compared to Stellar Biotechnologies' net margin of -1,782.64%. Jyong Biotech's return on equity of 0.00% beat Stellar Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Jyong BiotechN/A N/A N/A
Stellar Biotechnologies -1,782.64%-51.12%-48.37%

In the previous week, Jyong Biotech had 2 more articles in the media than Stellar Biotechnologies. MarketBeat recorded 2 mentions for Jyong Biotech and 0 mentions for Stellar Biotechnologies. Jyong Biotech's average media sentiment score of 0.00 equaled Stellar Biotechnologies'average media sentiment score.

Company Overall Sentiment
Jyong Biotech Neutral
Stellar Biotechnologies Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Stellar Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Jyong Biotech beats Stellar Biotechnologies on 5 of the 8 factors compared between the two stocks.

How does Stellar Biotechnologies compare to Anthem?

Anthem (NASDAQ:ANTX) and Stellar Biotechnologies (NASDAQ:SBOT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anthem
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Stellar Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Stellar Biotechnologies has higher revenue and earnings than Anthem. Stellar Biotechnologies is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnthemN/AN/A-$35.17M-$1.16N/A
Stellar Biotechnologies$210K212.44-$5.03M-$1.76N/A

90.5% of Anthem shares are owned by institutional investors. Comparatively, 1.7% of Stellar Biotechnologies shares are owned by institutional investors. 20.8% of Anthem shares are owned by company insiders. Comparatively, 7.8% of Stellar Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Anthem has a net margin of 0.00% compared to Stellar Biotechnologies' net margin of -1,782.64%. Stellar Biotechnologies' return on equity of -51.12% beat Anthem's return on equity.

Company Net Margins Return on Equity Return on Assets
AnthemN/A -55.04% -49.13%
Stellar Biotechnologies -1,782.64%-51.12%-48.37%

In the previous week, Anthem had 6 more articles in the media than Stellar Biotechnologies. MarketBeat recorded 6 mentions for Anthem and 0 mentions for Stellar Biotechnologies. Anthem's average media sentiment score of 0.00 equaled Stellar Biotechnologies'average media sentiment score.

Company Overall Sentiment
Anthem Neutral
Stellar Biotechnologies Neutral

Summary

Anthem beats Stellar Biotechnologies on 7 of the 11 factors compared between the two stocks.

How does Stellar Biotechnologies compare to Turn Therapeutics?

Stellar Biotechnologies (NASDAQ:SBOT) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

Turn Therapeutics has a consensus price target of $8.00, indicating a potential upside of 116.22%. Given Turn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Turn Therapeutics is more favorable than Stellar Biotechnologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stellar Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Turn Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Turn Therapeutics has lower revenue, but higher earnings than Stellar Biotechnologies. Turn Therapeutics is trading at a lower price-to-earnings ratio than Stellar Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stellar Biotechnologies$210K212.44-$5.03M-$1.76N/A
Turn TherapeuticsN/AN/A-$3.19M-$0.16N/A

1.7% of Stellar Biotechnologies shares are held by institutional investors. 7.8% of Stellar Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Turn Therapeutics has a net margin of 0.00% compared to Stellar Biotechnologies' net margin of -1,782.64%. Turn Therapeutics' return on equity of 0.00% beat Stellar Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Stellar Biotechnologies-1,782.64% -51.12% -48.37%
Turn Therapeutics N/A N/A N/A

In the previous week, Stellar Biotechnologies' average media sentiment score of 0.00 equaled Turn Therapeutics'average media sentiment score.

Company Overall Sentiment
Stellar Biotechnologies Neutral
Turn Therapeutics Neutral

Summary

Turn Therapeutics beats Stellar Biotechnologies on 8 of the 12 factors compared between the two stocks.

How does Stellar Biotechnologies compare to Aadi Bioscience?

Stellar Biotechnologies (NASDAQ:SBOT) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

Stellar Biotechnologies has higher earnings, but lower revenue than Aadi Bioscience. Stellar Biotechnologies is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stellar Biotechnologies$210K212.44-$5.03M-$1.76N/A
Aadi Bioscience$25.07M3.93-$65.76M-$2.35N/A

1.7% of Stellar Biotechnologies shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 7.8% of Stellar Biotechnologies shares are held by insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aadi Bioscience has a net margin of -246.06% compared to Stellar Biotechnologies' net margin of -1,782.64%. Stellar Biotechnologies' return on equity of -51.12% beat Aadi Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Stellar Biotechnologies-1,782.64% -51.12% -48.37%
Aadi Bioscience -246.06%-71.87%-57.28%

In the previous week, Aadi Bioscience had 1 more articles in the media than Stellar Biotechnologies. MarketBeat recorded 1 mentions for Aadi Bioscience and 0 mentions for Stellar Biotechnologies. Stellar Biotechnologies' average media sentiment score of 0.00 equaled Aadi Bioscience'saverage media sentiment score.

Company Overall Sentiment
Stellar Biotechnologies Neutral
Aadi Bioscience Neutral

Summary

Aadi Bioscience beats Stellar Biotechnologies on 6 of the 11 factors compared between the two stocks.

Get Stellar Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SBOT vs. The Competition

Export
MetricStellar BiotechnologiesPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$44.61M$886.55M$6.25B$11.77B
Dividend YieldN/A4.84%2.74%5.26%
P/E Ratio-4.761.7129.2527.07
Price / Sales212.44120.63504.6873.47
Price / CashN/A20.0743.3053.90
Price / Book3.957.609.676.69
Net Income-$5.03M-$4.80M$3.55B$332.64M

Stellar Biotechnologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SBOT
Stellar Biotechnologies
N/A$8.37
+4.2%		N/AN/A$44.61M$210KN/A25
CNTN
Hillstream Biopharma
0.0782 of 5 stars		$3.11
-5.8%		N/AN/A$176.21MN/AN/A2
MENS
Jyong Biotech
N/A$2.18
+0.5%		N/AN/A$165.74MN/AN/A31
ANTX
Anthem
0.1863 of 5 stars		$4.59
-3.3%		$2.00
-56.4%		N/A$165.06MN/AN/AN/A
TTRX
Turn Therapeutics
N/A$3.56
-1.1%		$8.00
+124.7%		N/A$106.05MN/AN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SBOT) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel